Cytonus announces Nature Biomedical Engineering publication

December 21, 2021

Cargocytes™, with a unique GPS-like navigation system, actively home to disease-specific signals and produce biologically active therapeutic within the target organ within hours after intravenous administration.


Cytonus Therapeutics Inc., a US-based biotechnology company developing an innovative drug-delivery platform technology called Cargocytes, today announced the publication of a peer reviewed research paper in the high impact journal, Nature Biomedical Engineering. The study showed that Cargocytes, which are genetically engineered with a GPS-like cellular navigation system, can selectively target disease tissue within hours after being administered and produce bioactive therapeutics at high levels for several days, thus allowing for a new modality in treating a wide range of difficult to treat diseases that require precision drug delivery.

These preclinical animal studies highlight the fact that the Cargocyte platform establishes a highly differentiated new category of drug-delivery and expands our view of precision drug delivery.

Results from the preclinical study provide further support for the innovative therapeutic potential of the Cargocyte technology platform. In addition, the Cargocyte’s unique ability to penetrate deep into target tissues and act as an in vivo “therapeutic factory” to produce bioactive immunomodulators at high concentrations within that targeted disease tissue is a major differentiation from simple drug-delivery approaches such as nanoparticles, red blood cells and exosome-based technologies. The groundbreaking study was led by Cytonus Therapeutics co-founder and Chief Science Officer, Richard Klemke Ph.D., Professor of Pathology at the University of California San Diego and Moores Cancer Center.

These preclinical animal studies highlight the fact that the Cargocyte platform establishes a highly differentiated new category of drug-delivery and expands our view of precision drug delivery,” said Klemke. “Our Cargocyte product represents a true vertical move in the field of drug delivery and medicine with real potential to impact multiple disease indications.”

Figure demonstrating Cargocyte Transmigration out of the vasculature (steps 1-3) and penetration into diseased tissues (step 4) followed by therapeutic production at the site of disease (step 4). (Graphic: Business Wire)

“What’s remarkable about this study is that it demonstrates the critical role drug localization plays in the delicate balance between efficacy and toxicity of a therapeutic. We are all looking for better outcomes with fewer side effects and we now have an elegant way to do this,” said Remo Moomiaie-Qajar, M.D., co-founder and CEO of Cytonus Therapeutics. “For the first time, therapeutics can be produced and secreted at the sites of disease in a controlled and safe manner. We believe this will allow for greater precision in delivering drugs and provide better efficacy and safety outcomes for patients.”

About Cargocyte™

Cargocytes are derived from enucleated stem cells and are uniquely engineered with specific disease targeting molecules to safely transport therapeutic payloads deep into difficult-to-reach targeted tissues. Cargocytes actively produce and release the therapeutic payload on site in a controlled, predictable, and safe manner. The proprietary Cargocyte technology platform is first-in-class and has numerous potential medical applications across unmet therapeutic areas. Cargocytes have been shown to deliver a wide range of therapeutic modalities including RNAs, small molecule drugs, viruses, and gene editing agents.

About Cytonus Therapeutics

Cytonus Therapeutics Inc. is a San Diego-based biotech company developing proprietary immunotherapeutic products to treat unmet needs in cancer, neurodegenerative, and inflammatory diseases.

For more information, we invite you to visit the Cytonus website at Join Cytonus on LinkedIn and follow its Twitter account at: @CytonusTx

Statements in this news release other than strictly historical facts, such as statements about Cytonus’ plans and strategies, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for its products, are forward-looking statements. The words “believe,” “expect,” “aim,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. The company undertakes no obligation to publicly update or revise any forward-looking statement. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.

Cytonus Media Contact
Name: Charles Gillespie
Title: Media Relations Coordinator